Safety and Liver Transduction Efficacy of rAAV5- cohPBGD in Nonhuman Primates: A Potential Therapy for Acute Intermittent Porphyria
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Acute intermittent porphyria (AIP) results from haplo-insufficient activity of porphobilinogen deaminase (PBGD) and is characterized clinically by life-threatening, acute neurovisceral attacks. To date, liver transplantation is the only curative option for AIP. The aim of the present preclinical nonhuman primate study was to determine the safety and transduction efficacy of an adeno-associated viral vector encoding PBGD (recombinant AAV serotype 5-codon-optimized human porphobilinogen deaminase, rAAV5-cohPBGD) administered intravenously as part of a safety program to start a clinical study in patients with AIP. Macaques injected with either 1 × 10(13) or 5 × 10(13) vector genomes/kg of clinical-grade rAAV5-cohPBGD were monitored by standardized clinical parameters, and vector shedding was analyzed. Liver transduction efficacy, biodistribution, vector integration, and histopathology at day 30 postvector administration were determined. There was no evidence of acute toxicity, and no adverse effects were observed. The vector achieved efficient and homogenous hepatocellular transduction, reaching transgenic PBGD expression levels equivalent to 50% of the naturally expressed PBGD mRNA. No cellular immune response was detected against the human PBGD or AAV capsid proteins. Integration site analysis in transduced liver cells revealed an almost random integration pattern supporting the good safety profile of rAAV5-cohPBGD. Together, data obtained in nonhuman primates indicate that rAAV5-cohPBGD represents a safe therapy to correct the metabolic defect present in AIP patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864 · cited 3×
“Regarding antivector immune response, patients with hemophilia B treated with AAV2 or AAV8 vector encoding factor IX developed specific cellular immune responses against the viral capsid (Mingozzi and High, 2011b; Nathwani et al. , 2011).”
Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970
Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893 · cited 3×
“AAV2 is the best characterized prototypic recombinant vector and has been employed in over 40 clinical trials (Mingozzi and High, 2011a).”
AAV serotype 2 vectors preferentially integrate into active genes in mice
Nakai, H., Montini, E., Fuess, S., Storm, T. A., Grompe, M., & Kay, M. A. (2003) · Nature Genetics · doi:10.1038/ng1179 · Cited by 392 · cited 2×
“In contrast to other studies (Nakai et al. , 2003; Li et al. , 2011), rAAV5-cohPBGD revealed a largely random integration pattern in NHP hepatocytes after intravenous delivery.”
Immune Responses to AAV in Clinical Trials
Mingozzi, F., & A. High, K. (2011) · Current Gene Therapy · doi:10.2174/156652311796150354 · Cited by 324
Mingozzi, F., Hasbrouck, N. C., Basner-Tschakarjan, E., Edmonson, S. A., Hui, D. J., Sabatino, D. E., Zhou, S., Wright, J. F., Jiang, H., Pierce, G. F., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080093 · Cited by 254 · cited 1×
“This expression profile favors immune tolerance to the transgene, in line with previously reported results (Mingozzi et al. , 2007).”
Pañeda, A., Vanrell, L., Mauleon, I., Crettaz, J. S., Berraondo, P., Timmermans, E. J., Beattie, S. G., Twisk, J., van Deventer, S., Prieto, J., et al. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.031 · Cited by 109 · cited 2×
“Unlike other serotypes, recombinant AAV serotype 5 (rAAV5) transduces nearly exclusively the liver after intravenous injection to mice (Paneda et al. , 2009).”
Self-citation
Cited by
Gil-Farina, I., Fronza, R., Kaeppel, C., Lopez-Franco, E., Ferreira, V., D'Avola, D., Benito, A., Prieto, J., Petry, H., Gonzalez-Aseguinolaza, G., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.52 · Cited by 179
Self-citationAdeno-Associated Virus Gene Therapy for Liver Disease
Kattenhorn, L. M., Tipper, C. H., Stoica, L., Geraghty, D. S., Wright, T. L., Clark, K. R., & Wadsworth, S. C. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.160 · Cited by 138
Han, S.-O., Ronzitti, G., Arnson, B., Leborgne, C., Li, S., Mingozzi, F., & Koeberl, D. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2016.12.010 · Cited by 78
Mietzsch, M., Casteleyn, V., Weger, S., Zolotukhin, S., & Heilbronn, R. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.050 · Cited by 65
Metadata
- Authors
- Pañeda, A., Lopez-Franco, E., Kaeppel, C., Unzu, C., Gil-Royo, A. G., D'Avola, D., Beattie, S. G., Olagüe, C., Ferrero, R., Sampedro, A., Mauleon, I., Hermening, S., Salmon, F., Benito, A., Gavira, J. J., Cornet, M. E., del Mar Municio, M., von Kalle, C., Petry, H., Prieto, J., Schmidt, M., Fontanellas, A., & González-Aseguinolaza, G.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2013-12
- Volume
- 24
- Issue
- 12
- Pages
- 1007-1017
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W1933310330
- Cited by
- 60
- References
- 8
- FWCI
- 5.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and Liver Transduction Efficacy of rAAV5- cohPBGD in Nonhuman Primates: A Potential Therapy for Acute Intermittent Porphyria. https://app.cochat.ai/papers/10.1089/hum.2013.166
- The paper
- Pañeda, A., Lopez-Franco, E., Kaeppel, C., Unzu, C., Gil-Royo, A. G., D'Avola, D., Beattie, S. G., Olagüe, C., Ferrero, R., Sampedro, A., Mauleon, I., Hermening, S., Salmon, F., Benito, A., Gavira, J. J., Cornet, M. E., del Mar Municio, M., von Kalle, C., Petry, H., . . . González-Aseguinolaza, G. (2013). Safety and Liver Transduction Efficacy of rAAV5- cohPBGD in Nonhuman Primates: A Potential Therapy for Acute Intermittent Porphyria. Human Gene Therapy. https://doi.org/10.1089/hum.2013.166
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.